Factory Mutual Insurance Co. maintained its position in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 85,600 shares of the medical research company’s stock at the close of the second quarter. Factory Mutual Insurance Co.’s holdings in Amgen were worth $14,743,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently bought and sold shares of the company. TrimTabs Asset Management LLC lifted its stake in Amgen by 88.9% during the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after acquiring an additional 288 shares during the period. Alpha Omega Wealth Management LLC lifted its stake in Amgen by 19.0% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after acquiring an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. lifted its stake in shares of Amgen by 0.6% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after purchasing an additional 4 shares during the period. American Beacon Advisors Inc. bought a new position in shares of Amgen in the 1st quarter worth approximately $106,000. Finally, Nelson Roberts Investment Advisors LLC bought a new position in shares of Amgen in the 1st quarter worth approximately $121,000. Institutional investors and hedge funds own 78.09% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Amgen Inc. (AMGN) Position Held by Factory Mutual Insurance Co.” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://sportsperspectives.com/2017/09/19/amgen-inc-amgn-position-held-by-factory-mutual-insurance-co.html.
Amgen Inc. (NASDAQ:AMGN) traded down 0.13% on Tuesday, hitting $186.23. 800,467 shares of the company were exchanged. The stock’s 50-day moving average price is $175.65 and its 200-day moving average price is $169.26. The stock has a market capitalization of $135.89 billion, a P/E ratio of 16.96 and a beta of 1.35. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $191.10.
Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.84 EPS. On average, equities research analysts anticipate that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were paid a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a dividend yield of 2.47%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s payout ratio is 41.93%.
AMGN has been the topic of several recent research reports. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $189.00 price objective on shares of Amgen in a research note on Friday, June 30th. BidaskClub upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Jefferies Group LLC reiterated a “hold” rating and issued a $180.00 price objective on shares of Amgen in a research note on Monday, May 22nd. Credit Suisse Group set a $177.00 price objective on shares of Amgen and gave the stock a “hold” rating in a research note on Friday, July 14th. Finally, Morgan Stanley increased their price objective on shares of Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 13th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. Amgen has a consensus rating of “Buy” and an average target price of $186.14.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.